Silencing of tissue factor by antisense deoxyoligonucleotide prevents monocrotaline/LPS renal injury in mice
Mohamed Sadek Abdel-Bakky1, Mohamed A Hammad, Larry A Walker
1National Center For Natural Products Research, School of Pharmacy, University of Mississippi, University, MS 38677, USA.
Abstract:
Tissue factor (TF) is involved in monocrotaline (MCT)/lipopolysaccharide (LPS) hepatotoxicity. It is not known whether MCT/LPS can cause renal toxicity and whether TF is involved in this toxicity. Thus, the present study was undertaken to investigate the potential renal toxicity after MCT/LPS co-treatment and the involvement of TF in this toxicity. MCT was delivered to ND4 male mice (200 mg/kg) per os followed 4 h later by treatment with LPS ip (6 mg/kg) to investigate its effect on kidney. We injected TF antisense oligonucleotide (TF-AS) intravenously (i.v) in mice prior to LPS treatment, to block TF, and measured their blood urea nitrogen (BUN), creatinine (CRE), alkaline phosphatase (ALP), and potassium. In MCT/LPS co-treated group, fibrin was detected on the glomerular capillary lumina, distal tubules of renal cortex, and the necrotic tubules of renal medulla. An elevation of BUN, creatinine, and the BUN/creatinine ratio was seen in mice with MCT/LPS co-treatment, compared to animals receiving LPS or MCT alone. Simultaneously, an aggressive tubular necrosis was seen in the medullary tubules in the same group which may account for the oliguria observed in these animals. Fourfold inductions in the plasma TF level was detected at 10 h after MCT/LPS co-treatment which increased to 18-fold at 24 h. Increased blood level of leptin, interleukin-6 (IL-6) and downregulation of tubular chemokine (C-X-C motif) ligand 16 (CXCL16) are characteristic features in MCT/LPS co-treated animal. On the other hand, mice injected with TF-AS in the presence of MCT/LPS co-treatment showed no elevation of the blood BUN, creatinine, potassium, and normal levels of the proinflammatory molecules. TF-AS injection significantly prevented glomerular and tubular fibrin deposition, tubular necrosis, and improvement of the animal survivability. Renal toxicity involving TF can be prevented successfully by the use of TF-AS.
Insights
Monocrotaline (MCT) and lipopolysaccharide (LPS) co-treatment causes kidney damage by increasing tissue factor (TF). Blocking TF with TF antisense oligonucleotide (TF-AS) prevents this renal toxicity and improves survival.
Area of Science:
- Nephrology
- Toxicology
- Hematology
Background:
- Tissue factor (TF) is implicated in monocrotaline (MCT)/lipopolysaccharide (LPS) induced liver injury.
- The role of TF in MCT/LPS-induced kidney toxicity remains uninvestigated.
Purpose of the Study:
- To investigate the potential renal toxicity of MCT/LPS co-treatment.
- To determine the involvement of TF in MCT/LPS-induced renal toxicity.
Main Methods:
- Mice were co-treated with MCT and LPS.
- TF was blocked using TF antisense oligonucleotide (TF-AS).
- Renal function markers (BUN, creatinine), fibrin deposition, tubular necrosis, and plasma TF levels were assessed.
Main Results:
- MCT/LPS co-treatment led to elevated BUN and creatinine, tubular necrosis, and increased plasma TF levels.
- TF-AS administration prevented these adverse effects, including fibrin deposition and necrosis.
- TF-AS treatment normalized proinflammatory markers and improved animal survival.
Conclusions:
- MCT/LPS co-treatment induces significant renal toxicity.
- TF plays a crucial role in mediating this renal damage.
- TF blockade is a potential therapeutic strategy to prevent MCT/LPS-induced nephrotoxicity.
More Related Videos
15:55Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy
Published on: June 21, 2013
11:07Inducing Acute Lung Injury in Mice by Direct Intratracheal Lipopolysaccharide Instillation
Published on: July 6, 2019
